Literature DB >> 27239169

Immunological Mechanisms in Breast Cancer - from Bench to Bedside.

Carsten Denkert1, Florian Schütz2.   

Abstract

Year:  2016        PMID: 27239169      PMCID: PMC4881276          DOI: 10.1159/000446266

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  14 in total

1.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

2.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

3.  Two dimensions in targeting HER2.

Authors:  Mark M Moasser
Journal:  J Clin Oncol       Date:  2014-05-27       Impact factor: 44.544

4.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

5.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Authors:  Carsten Denkert; Gunter von Minckwitz; Jan C Brase; Bruno V Sinn; Stephan Gade; Ralf Kronenwett; Berit M Pfitzner; Christoph Salat; Sherene Loi; Wolfgang D Schmitt; Christian Schem; Karin Fisch; Silvia Darb-Esfahani; Keyur Mehta; Christos Sotiriou; Stephan Wienert; Peter Klare; Fabrice André; Frederick Klauschen; Jens-Uwe Blohmer; Kristin Krappmann; Marcus Schmidt; Hans Tesch; Sherko Kümmel; Peter Sinn; Christian Jackisch; Manfred Dietel; Toralf Reimer; Michael Untch; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2014-12-22       Impact factor: 44.544

Review 6.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

Review 7.  Natural and therapy-induced immunosurveillance in breast cancer.

Authors:  Guido Kroemer; Laura Senovilla; Lorenzo Galluzzi; Fabrice André; Laurence Zitvogel
Journal:  Nat Med       Date:  2015-10       Impact factor: 53.440

Review 8.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

Review 9.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors:  Peter Savas; Roberto Salgado; Carsten Denkert; Christos Sotiriou; Phillip K Darcy; Mark J Smyth; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

Review 10.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.